Myelodysplastic Syndrome Clinical Trial
Long-term Follow-up of Participants With Cerebral Adrenoleukodystrophy Who Were Treated With Lenti-D Drug Product
This is a multi-center, long-term safety and efficacy follow-up study for participants with cerebral adrenoleukodystrophy (CALD) who have received Lenti-D Drug Product in a parent clinical study.
After completing a parent clinical study (approximately 2 years), eligible participants will be followed for an additional 13 years for a total of 15 years post-drug product infusion. No investigational drug product will be administered in this study.
Provision of written informed consent for this study by the participant or participant's parent(s)/ legal guardian(s) and written informed assent by participant, if applicable
Have received Lenti-D Drug Product in a parent clinical study
Able to comply with study requirements
There are no exclusion criteria for this Study
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 8 Locations for this study
Los Angeles California, 90095, United States
Palo Alto California, 94304, United States
Boston Massachusetts, 02115, United States
Minneapolis Minnesota, 55455, United States
Caba , , Argentina
North Adelaide , , Australia
São Paulo , 05403, Brazil
Le Kremlin-Bicêtre Cedex, 94275, France
Leipzig , 04103, Germany
Utrecht , 3584, Netherlands
London , , United Kingdom
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.